PayPal Holdings, Inc. (NASDAQ:PYPL) [Trend Analysis] climbed reacts as active mover, shares a gain 0.10% to traded at $41.60 and the percentage gap between open changing to regular change was 0.22%. A shareholder rights firm, Lundin Law PC reported a class action lawsuit against PayPal Holdings, Inc. (PYPL), eBay Inc. (EBAY), and certain of its officers concerning possible violations of federal securities laws. The Complaint alleges that during the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about its business, operations, and prospects.
Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: PayPal’s Venmo service was allegedly participating in unfair trade practices; the announcement of the above allegations was likely to affect PayPal’s profit on its Venmo service and/or thus, PayPal’s public statements were materially false and misleading at all relevant times. The firm’s current ratio calculated as 1.50 for the most recent quarter. The firm past twelve months price to sales ratio was 4.81 and price to cash ratio remained 9.86. As far as the returns are concern, the return on equity was recorded as 10.00% and return on investment was 8.70% while its return on asset stayed at 4.60%. The firm has total debt to equity ratio measured as 0.00.
Akers Biosciences, Inc. (NASDAQ:AKER) [Trend Analysis] attempts to attain leading position in street, Shares price changes as it -3.85% to close at $1.25 with the total traded volume of 45122 shares. Akers Biosciences, Inc. (NASDAQ:AKER) reported that closing of its previously declared underwritten public offering of 1,667,000 shares of common stock at a public offering price of $1.20 per share together with the issuance of 833,500 five-year warrants to purchase common stock with an exercise price of $1.50. In addition, the underwriters exercised the over-allotment option to purchase an additional 122,500 shares of common stock and 61,250 warrants to purchase common stock.
The gross proceeds from the offering, excluding any proceeds on the exercise of the warrants, are expected to be approximately $2,147,400, before deducting the underwriting discount and estimated offering expenses. The funds raised will be used for working capital as well as to accelerate growth in the US and in international markets, further develop new consumers and launch new diagnostic products. The firm has institutional ownership of 12.00%, while insider ownership included 19.40%. Its price to sales ratio ended at 3.32. AKER attains analyst recommendation of 2.00 with week’s performance of -26.47%.